ANAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AnaptysBio Inc (ANAB) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite recent price declines, the company's strong financial performance, positive analyst sentiment, and upcoming catalysts make it an attractive long-term investment opportunity.
The stock shows a bullish trend with moving averages aligned positively (SMA_5 > SMA_20 > SMA_200). The MACD histogram is above zero, indicating positive momentum, though it is contracting. RSI is neutral at 57.288, and the stock is trading near its pivot level of 57.241, with key support at 53.119 and resistance at 61.363.
Strong Q4 financial performance with a 151.1% YoY revenue increase and EPS exceeding expectations.
Analyst upgrades and increased price targets, with the highest target at $
Upcoming spin-off of the biopharma portfolio and Phase 3 development updates for rosnilimab in Q
Stock repurchase program reducing outstanding shares by 11.2%.
Insider selling has increased significantly by 189.75% over the last month.
Net income and EPS have declined YoY despite revenue growth.
Recent price drop of -5.40% in the regular market and additional declines in pre- and post-market trading.
In Q4 2025, AnaptysBio reported a 151.1% YoY revenue increase to $108.25 million, showcasing strong top-line growth. However, net income dropped by -327.75% YoY to $49.61 million, and EPS fell by -348.61% YoY to 1.79. The gross margin remained stable at 100%. The company has $311.6 million in cash and investments, ensuring sufficient funding for future operations.
Analyst sentiment is highly positive, with multiple firms raising price targets recently. Stifel raised the target to $85, Barclays to $79, and H.C. Wainwright to $66, all maintaining Buy or Overweight ratings. Analysts are optimistic about the company's spin-off plans and its differentiated drug pipeline.
